Literature DB >> 12586773

Opposing roles for the insulin-like growth factor (IGF)-II and mannose 6-phosphate (Man-6-P) binding activities of the IGF-II/Man-6-P receptor in the growth of prostate cancer cells.

Beverly S Schaffer1, Ming-Fong Lin, James C Byrd, Jung H Y Park, Richard G MacDonald.   

Abstract

The IGF-II/mannose 6-phosphate (Man-6-P) receptor (IGF2R) binds IGF-II and Man-6-P-bearing ligands at distinct binding sites. Analysis of IGF2R expression and function suggested that decreased IGF2R expression could partly account for the increased growth of lymph node carcinoma of the prostate (LNCaP) human prostate cancer cells observed with increasing passage in culture. However, LNCaP cells that expressed a Myc-tagged IGF2R (IGF2RMyc) proliferated more rapidly than control cells transfected with the empty vector. LNCaP cells expressing a mutant IGF2R incompetent to bind IGF-II (IGF2RMyc I/T) proliferated more rapidly than both vector-transfected cells and cells expressing the IGF2RMyc. In contrast, forced expression of IGF2RMyc in PC-3 human prostate cancer cells resulted in decreased proliferation, compared with control cells. As in LNCaP cells, PC-3 cells expressing IGF2RMyc I/T proliferated more rapidly than vector-transfected cells. The subcellular distribution and ability to internalize cell-surface IGF-II of IGF2RMyc were indistinguishable from endogenous IGF2R in PC-3 cells. These data suggest that the IGF-II- and Man-6-P-binding functions of the IGF2R have opposing activities, with respect to growth of prostate cancer cells. The magnitude of each activity in a given cell type seems to determine whether the net effect of the IGF2R on cell growth is inhibitory or stimulatory.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586773     DOI: 10.1210/en.2002-220751

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Dominant-negative effect of truncated mannose 6-phosphate/insulin-like growth factor II receptor species in cancer.

Authors:  Jodi L Kreiling; Michelle A Montgomery; Joseph R Wheeler; Jennifer L Kopanic; Christopher M Connelly; Megan E Zavorka; Jenna L Allison; Richard G Macdonald
Journal:  FEBS J       Date:  2012-07-02       Impact factor: 5.542

2.  Differential expression of IGF components and insulin receptor isoforms in human seminoma versus normal testicular tissue.

Authors:  Tanja Pascale Neuvians; Isabella Gashaw; Andrea Hasenfus; Axel Hacherhäcker; Elke Winterhager; Rainer Grobholz
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

Review 3.  Heterotrimeric G proteins and the single-transmembrane domain IGF-II/M6P receptor: functional interaction and relevance to cell signaling.

Authors:  C Hawkes; A Amritraj; R G Macdonald; J H Jhamandas; S Kar
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

Review 4.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

5.  Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk.

Authors:  Lang Wu; Xiang Shu; Jiandong Bao; Xingyi Guo; Zsofia Kote-Jarai; Christopher A Haiman; Rosalind A Eeles; Wei Zheng
Journal:  Cancer Res       Date:  2019-07-23       Impact factor: 12.701

6.  IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas.

Authors:  Cathrine Hoyo; Joellen M Schildkraut; Susan K Murphy; Wong-Ho Chow; Thomas L Vaughan; Harvey Risch; Jeffrey R Marks; Randy L Jirtle; Brian Calingaert; Brian Calingeart; Susan Mayne; Joseph Fraumeni; Marilie D Gammon
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

7.  The mannose 6-phosphate-binding sites of M6P/IGF2R determine its capacity to suppress matrix invasion by squamous cell carcinoma cells.

Authors:  Olivia C Probst; Evren Karayel; Nicole Schida; Elisabeth Nimmerfall; Elisabeth Hehenberger; Verena Puxbaum; Lukas Mach
Journal:  Biochem J       Date:  2013-04-01       Impact factor: 3.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.